Nitric oxide exerts protective effects against bleomycin-induced pulmonary fibrosis in mice

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Noguchi, Shingo ^a   Yatera, Kazuhiro ^a   Wang, Ke Yong ^a   Oda, Keishi ^a   Akata, Kentarou ^a   Yamasaki, Kei ^a   Kawanami, Toshinori ^a   Ishimoto, Hiroshi ^a   Toyohira, Yumiko ^b   Shimokawa, Hiroaki ^c   Yanagihara, Nobuyuki ^b   Tsutsui, Masato ^d   Mukae, Hiroshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOSORBIDE DINITRATE; NITRIC OXIDE; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CELL COUNT; CONTROLLED STUDY; GENE EXPRESSION; GENE INACTIVATION; GENOTYPE; HISTOPATHOLOGY; LEUKOCYTE DIFFERENTIAL COUNT; LONG TERM CARE; LUNG LAVAGE; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TOTAL CELL COUNT; WEIGHT CHANGE; WILD TYPE; ANIMAL; CHEMICALLY INDUCED; KNOCKOUT MOUSE; MALE; PATHOLOGY; PULMONARY FIBROSIS;

ANIMALS; BLEOMYCIN; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE; PULMONARY FIBROSIS;

EID: 84905990049     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-014-0092-3     Document Type: Article

References (44)

1. Green FH. Overview of pulmonary fibrosis. Chest 2002, 122:334S-339S. 10.1378/chest.122.6_suppl.334S, 12475811.
2. Janssen W, Pullamsetti SS, Cooke J, Weissmann N, Guenther A, Schermuly RT. The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. J Pathol 2013, 229:242-249. 10.1002/path.4127, 23097221.
3. Tsutsui M, Shimokawa H, Morishita T, Nakashima Y, Yanagihara N. Development of genetically engineered mice lacking all three nitric oxide synthases. J Pharmacol Sci 2006, 102:147-154. 17031076.
4. Sugiura H, Ichinose M. Nitrative stress in inflammatory lung diseases. Nitric Oxide 2011, 25:138-144. 10.1016/j.niox.2011.03.079, 21440655.
5. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004, 84:731-765. 10.1152/physrev.00034.2003, 15269335.
6. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005, 172:417-422. 15894605.
7. Saleh D, Barnes PJ, Giaid A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997, 155:1763-1769. 9154889.
8. Lakari E, Soini Y, Sa¨ily M, Koistinen P, Pa¨a¨kko¨ P, Kinnula VL. Inducible nitric oxide synthase, but not xanthine oxidase, is highly expressed in interstitial pneumonias and granulomatous diseases of human lung. Am J Clin Pathol 2002, 117:132-142. 10.1309/W7T9-HW9V-V94B-R9KM, 11789718.
9. Almude´ver P, Milara J, De Diego A, Serrano-Mollar A, Xaubet A, Perez-Vizcaino F, Cogolludo A, Cortijo J. Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis. Thorax 2013, 68:938-948. 10.1136/thoraxjnl-2013-203408, 23739137.
10. Yoshimura S, Nishimura Y, Nishiuma T, Yamashita T, Kobayashi K, Yokoyama M. Overexpression of nitric oxide synthase by the endothelium attenuates bleomycin-induced lung fibrosis and impairs MMP-9/TIMP-1 balance. Respirology 2006, 11:546-556. 10.1111/j.1440-1843.2006.00894.x, 16916326.
11. Chung MP, Monick MM, Hamzeh NY, Butler NS, Powers LS, Hunninghake GW. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am J Respir Cell Mol Biol 2003, 29:375-380. 10.1165/rcmb.2003-0029OC, 12676806.
12. Genovese T, Cuzzocrea S, Di Paola R, Failla M, Mazzon E, Sortino MA, Frasca G, Gili E, Crimi N, Caputi AP, Vancheri C. Inhibition or knock out of inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury. Respir Res 2005, 6:58. 10.1186/1465-9921-6-58, 15955252.
13. Hsu YC, Wang LF, Chien YW. Nitric oxide in the pathogenesis of diffuse pulmonary fibrosis. Free Radic Biol Med 2007, 42:599-607. 10.1016/j.freeradbiomed.2006.11.031, 17291983.
14. Yildirim Z, Turkoz Y, Kotuk M, Armutcu F, Gurel A, Iraz M, Ozen S, Aydogdu I, Akyol O. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 2004, 11:156-165. 10.1016/j.niox.2004.07.011, 15491848.
15. Davis DW, Weidner DA, Holian A, McConkey DJ. Nitric oxide-dependent activation of p53 suppresses bleomycin-induced apoptosis in the lung. J Exp Med 2000, 192:857-869. 10.1084/jem.192.6.857, 10993916.
16. D'Alessio FR, Tsushima K, Aggarwal NR, Mock JR, Eto Y, Garibaldi BT, Files DC, Avalos CR, Rodriguez JV, Waickman AT, Reddy SP, Pearse DB, Sidhaye VK, Hassoun PM, Crow MT, King LS. Resolution of experimental lung injury by monocyte-derived inducible nitric oxide synthase. J Immunol 2012, 189:2234-2245. 10.4049/jimmunol.1102606, 22844117.
17. Morishita T, Tsutsui M, Shimokawa H, Sabanai K, Tasaki H, Suda O, Nakata S, Tanimoto A, Wang KY, Ueta Y, Sasaguri Y, Nakashima Y, Yanagihara N. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci U S A 2005, 102:10616-10621. 10.1073/pnas.0502236102, 16024729.
18. Furuno Y, Morishita T, Toyohira Y, Yamada S, Ueno S, Morisada N, Sugita K, Noguchi K, Sakanashi M, Miyata H, Tanimoto A, Sasaguri Y, Shimokawa H, Otsuji Y, Yanagihara N, Tamura M, Tsutsui M. Crucial vasculoprotective role of the whole nitric oxide synthase system in vascular lesion formation in mice: Involvement of bone marrow-derived cells. Nitric Oxide 2011, 25:350-359. 10.1016/j.niox.2011.06.007, 21767657.
19. Mizuta M, Hirano S, Hiwatashi N, Tateya I, Kanemaru SI, Nakamura T, Ito J. Effect of astaxanthin on vocal fold wound healing. Laryngoscope 2014, 124:E1-E7. 23686840.
20. Tasaki T, Yamada S, Guo X, Tanimoto A, Wang KY, Nabeshima A, Kitada S, Noguchi H, Kimura S, Shimajiri S, Kohno K, Ichijo H, Sasaguri Y. Apoptosis signal-regulating kinase 1 deficiency attenuates vascular injury-induced neointimal hyperplasia by suppressing apoptosis in smooth muscle cells. Am J Pathol 2013, 182:597-609. 10.1016/j.ajpath.2012.10.008, 23178077.
21. Tokuda A, Itakura M, Onai N, Kimura H, Kuriyama T, Matsushima K. Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol 2000, 164:2745-2751. 10.4049/jimmunol.164.5.2745, 10679116.
22. Yamashita T, Yamamoto E, Kataoka K, Nakamura T, Matsuba S, Tokutomi Y, Dong YF, Ichijo H, Ogawa H, Kim-Mitsuyama S. Apoptosis signal-regulating kinase-1 is involved in vascular endothelial and cardiac remodeling caused by nitric oxide deficiency. Hypertension 2007, 50:519-524. 10.1161/HYPERTENSIONAHA.107.092049, 17646574.
23. Mihout F, Shweke N, Bige´ N, Jouanneau C, Dussaule JC, Ronco P, Chatziantoniou C, Boffa JJ. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis. J Pathol 2011, 223:37-45. 10.1002/path.2769, 20845411.
24. Hogaboam CM, Gallinat CS, Bone-Larson C, Chensue SW, Lukacs NW, Strieter RM, Kunkel SL. Collagen deposition in a non-fibrotic lung granuloma model after nitric oxide inhibition. Am J Pathol 1998, 153:1861-1872. 10.1016/S0002-9440(10)65700-8, 9846976.
25. Hesslinger C, Strub A, Boer R, Ulrich WR, Lehner MD, Braun C. Inhibition of inducible nitric oxide synthase in respiratory diseases. Biochem Soc Trans 2009, 37:886-891. 10.1042/BST0370886, 19614613.
26. Kilbourn RG, Szabo´ C, Traber DL. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock 1997, 7:235-246. 10.1097/00024382-199704000-00001, 9110408.
27. Jang AS, Lee JU, Choi IS, Park KO, Lee JH, Park SW, Park CS. Expression of nitric oxide synthase, aquaporin 1 and aquaporin 5 in rat after bleomycin inhalation. Intensive Care Med 2004, 30:489-495. 10.1007/s00134-003-2129-9, 14767587.
28. Yatera Y, Shibata K, Furuno Y, Sabanai K, Morisada N, Nakata S, Morishita T, Toyohira Y, Wang KY, Tanimoto A, Sasaguri Y, Tasaki H, Nakashima Y, Shimokawa H, Yanagihara N, Otsuji Y, Tsutsui M. Severe dyslipidaemia, atherosclerosis, and sudden cardiac death in mice lacking all NO synthases fed a high-fat diet. Cardiovasc Res 2010, 87:675-682. 10.1093/cvr/cvq092, 20304785.
29. Zhu Y, Liu Y, Zhou W, Xiang R, Jiang L, Huang K, Xiao Y, Guo Z, Gao J. A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir Res 2010, 11:34. 10.1186/1465-9921-11-34, 20302663.
30. Bellocq A, Azoulay E, Marullo S, Flahault A, Fouqueray B, Philippe C, Cadranel J, Baud L. Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol 1999, 21:128-136. 10.1165/ajrcmb.21.1.3379, 10385601.
31. Shibata K, Yatera Y, Furuno Y, Sabanai K, Morisada N, Nakata S, Morishita T, Yamazaki F, Tanimoto A, Sasaguri Y, Tasaki H, Nakashima Y, Shimokawa H, Yanagihara N, Otsuji Y, Tsutsui M. Spontaneous development of left ventricular hypertrophy and diastolic dysfunction in mice lacking all nitric oxide synthases. Circ J 2010, 74:2681-2692. 10.1253/circj.CJ-10-0277, 20966596.
32. Vyas-Read S, Shaul PW, Yuhanna IS, Willis BC. Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2007, 293:L212-L221. 17496059.
33. Kinoshita K, Aono Y, Azuma M, Kishi J, Takezaki A, Kishi M, Makino H, Okazaki H, Uehara H, Izumi K, Sone S, Nishioka Y. Antifibrotic Effects of Focal Adhesion Kinase Inhibitor in Bleomycin-Induced Pulmonary Fibrosis in Mice. Am J Respir Cell Mol Biol 2013, 49:536-543. 10.1165/rcmb.2012-0277OC, 23642017.
34. Keil A, Blom IE, Goldschmeding R, Rupprecht HD. Nitric oxide down-regulates connective tissue growth factor in rat mesangial cells. Kidney Int 2002, 62:401-411. 10.1046/j.1523-1755.2002.00462.x, 12110001.
35. Parada C, Li J, Iwata J, Suzuki A, Chai Y. CTGF mediates Smad-dependent transforming growth factor β signaling to regulate mesenchymal cell proliferation during palate development. Mol Cell Biol 2013, 33:3482-3493. 10.1128/MCB.00615-13, 23816882.
36. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008, 590:400-408. 10.1016/j.ejphar.2008.06.046, 18598692.
37. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999, 341:1264-1269. 10.1056/NEJM199910213411703, 10528036.
38. Persoons JH, Schornagel K, Tilders FF, De Vente J, Berkenbosch F, Kraal G. Alveolar macrophages autoregulate IL-1 and IL-6 production by endogenous nitric oxide. Am J Respir Cell Mol Biol 1996, 14:272-278. 10.1165/ajrcmb.14.3.8845178, 8845178.
39. Thomassen MJ, Buhrow LT, Connors MJ, Kaneko FT, Erzurum SC, Kavuru MS. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am J Respir Cell Mol Biol 1997, 17:279-283. 10.1165/ajrcmb.17.3.2998m, 9308913.
40. Inoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T, Takeshita A, Kitamoto S, Egashira K, Hara N. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004, 286:L1038-L1044. 15064241.
41. Baran CP, Opalek JM, McMaken S, Newland CA, O'Brien JM, Hunter MG, Bringardner BD, Monick MM, Brigstock DR, Stromberg PC, Hunninghake GW, Marsh CB. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176:78-89. 17431224.
42. Sakamoto T, Ishibashi T, Sakamoto N, Sugimoto K, Egashira K, Ohkawara H, Nagata K, Yokoyama K, Kamioka M, Ichiki T, Sugimoto N, Kurabayashi M, Suzuki K, Takuwa Y, Maruyama Y. Endogenous NO blockade enhances tissue factor expression via increased Ca2+ influx through MCP-1 in endothelial cells by monocyte adhesion. Arterioscler Thromb Vasc Biol 2005, 25:2005-2011. 10.1161/01.ATV.0000178171.61754.cd, 16020745.
43. Zhao Q, Egashira K, Inoue S, Usui M, Kitamoto S, Ni W, Ishibashi M, Hiasa Ki K, Ichiki T, Shibuya M, Takeshita A. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 2002, 105:1110-1115. 10.1161/hc0902.104718, 11877364.
44. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996, 271:17779-17784. 10.1074/jbc.271.30.17779, 8663511.